<DOC>
	<DOCNO>NCT02240992</DOCNO>
	<brief_summary>The purpose study compare efficacy mesenchymal stem cell ( MSCs ) without granulocyte colony-stimulating factor ( G-CSF ) mobilize peripheral stem cell ( PBSC ) treat patient experience poor graft function delay platelet engraftment allogeneic hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>MSCs With Without Peripheral Blood Stem Cell Treatment Poor Graft Function Delayed Platelet Engraftment</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) cure many hematologic disease . However , 5-27 % patient would suffer poor graft function ( PGF ) recipient might develop delayed platelet engraftment ( DPE ) allo-HSCT . These complication associate considerable mortality relate infection hemorrhagic complication . Treatment PGF DPE usually involve hematopoietic growth factor granulocyte colony-stimulating factor ( G-CSF ) thrombopoietin ( TPO ) , second transplantation , method dismal effect even significant risk graft-versus-host disease ( GVHD ) . Mesenchymal stem cell ( MSCs ) form multipotent adult stem cell isolate bone marrow ( BM ) , adipose tissue , cord blood . Clinical application human MSCs include improve hematopoietic engraftment , prevent treat graft-versus-host disease allo-HSCT . Some study show MSCs combine PBSC cord blood could useful improve engraftment HSCT . Several report suggest MSCs might effective treatment PGF . However , efficacy MSCs single-drug treatment PGF DPE unsatisfactory previous study . Therefore , present study , G-CSF mobilize PBSC use combined MSCs patient PGF DPE allo-HSCT .</detailed_description>
	<mesh_term>Hematologic Diseases</mesh_term>
	<criteria>Ageï¼š1465 year PGF DPE alloHSCT Subjects ( legally acceptable representative ) must sign informed consent document Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Poor Graft Function</keyword>
	<keyword>Delayed platelet engraftment</keyword>
	<keyword>Peripheral Blood Stem Cell</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
</DOC>